Citations

Clear

1906 citation(s) found for "Yu, Frank".

Anatomy of the Superior and Inferior Labial Arteries Revised: An Ultrasound Investigation and Implication for Lip Volumization
Alfertshofer, Michael , Schenck, Thilo L., Bertucci, Vince , Beleznay, Katie, Ascher, Benjamin, Lachmann, Nirusha, Swift, Arthur, Frank, Konstantin , Alfertshofer, Michael , Cotofana, Sebastian , Green, Jeremy B.

Mayo Clinic

Aesthetic Surgery Journal | May 29, 2020 | Volume: 40 | Issue: 12 | Pages: 1327-1335

10.1093/asj/sjaa137 | PMID 32469050 Get It

Abstract Background Lips are considered a key element of facial attractiveness due to their central position in the face and their elemental role in verbal and nonverbal communication. Objectives The authors sought to provide clinically relevant information on the 3-dimensional pathway of the superior and inferior labial arteries within the lips to increase safety during labial soft tissue filler injections. Methods The study enrolled 41 healthy volunteers with a mean age of 26.17 ± 9.6 years and a mean body mass index of 23.09 ± 2.3 kg/m2. Ultrasound imaging was performed at 6 different locations. The position of the labial arteries within the lips, depth of the arteries, cranio-caudal location of each artery in relation to the vermilion border, and diameter of the superior/inferior labial arteries were recorded. Results The most frequent location of both the superior and inferior labial arteries was the submucosal plane (58.5%) followed by intramuscular (36.2%) and subcutaneous (5.3%) planes. The depth of the superior labial artery in the upper lip was 5.6 ± 0.13 mm, whereas the depth of the inferior labial artery in the lower lip was 5.2 ± 0.14 mm. Both arteries were more frequently located within the red lip: upper lip (83% vs 18.7%) and lower lip (86.2% vs 13.8%). In the midline, the artery coursed within the red lip in all investigated volunteers. Conclusions Clinically, results of this study favor a superficial injection plane for lip volumization procedures. A perpendicular approach to the lip (coming from the cutaneous lip) might increase safety because the artery is located most frequently within the red lip.
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society o
Stanway, Susannah , Brezden‐Masley, Christine , Cohen‐Solal, Alain , Tocchetti, Carlo G. , Moslehi, Javid J. , Groarke, John D. , Bergler‐Klein, Jutta , Khoo, Vincent , Tan, Li Ling , Anker, Markus S. , Haehling, Stephan von , Maack, Christoph , Ky, Bonnie , Neilan, Tomas G. , Rosen, Stuart D. , Iakobishvili, Zaza , Sverdlov, Aaron L. , Hajjar, Ludhmila Abrahão , Macedo, Ariane Vieira Scarlatelli , Manisty, Charlotte , Farmakis, Dimitrios , Boer, Rudolf A. de , Skouri, Hadi , Suter, Thomas, Fradley, Michael G. , Herrmann, Joerg , Cornell, Robert F. , Wechelaker, Ashutosh, Mauro, Michael J. , Milojković, Dragana , Lavallade, Hugues de , Seferović, Petar , Chioncel, Ovidiu , Andrés, María Sol , Wright, David J. , de Boer, Rudolf A , Ky, Bonnie , Sverdlov, Aaron L , Tocchetti, Carlo Gabriele , Lyon, Alexander R. , Dent, Susan , Earl, Helena , Pudil, Radek , Barac, Ana , Thavendiranathan, Paaladinesh , Belenkov, Yu. N. , Ciardiello, Fortunato , Cardinale, Daniela , Witteles, Ronald , Ruschitzka, Frank T. , Coats, Andrew J.S. , Thum, Thomas , Bauersachs, Johann , López‐Fernández, Teresa , Plummer, Chris , Lenihan, Daniel

Mayo Clinic

European Journal of Heart Failure | May 28, 2020 | Volume: 22 | Issue: 11 | Pages: 1945-1960

10.1002/ejhf.1920 | PMID 32463967 Get It

Abstract This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study
Khalil, R , Antonio, Leen , Laurent, Michaël R. , David, Karel , Kim, Na Ri , Evenepoel, Pieter , Heuser, Alexander , Cavalier, Etienne , Claessens, Frank , Vanderschueren, Dirk , Decallonne, Brigitte , Eisenhauer, Anton , Khosla, Sundeep , Claessens, Frank

Mayo Clinic

European Journal of Endocrinology | May 26, 2020 | Volume: 183 | Issue: 2 | Pages: 181-189

10.1530/eje-20-0348 | PMID 32454455 Get It

Objective Long-term androgen deprivation therapy (ADT) negatively influences bone. The short-term effects on bone and mineral homeostasis are less known. Therefore, we aimed to investigate the early effects of ADT on calcium/phosphate homeostasis and bone turnover. Design Prospective cohort study. Methods Eugonadal adult, male sex offenders, who were referred for ADT to the endocrine outpatient clinic, received cyproterone acetate. Changes in blood markers of calcium/phosphate homeostasis and bone turnover between baseline and first follow-up visit were studied. Results Of 26 screened patients, 17 were included. The median age was 44 (range 20–75) years. The median time interval between baseline and first follow-up was 13 (6–27) weeks. Compared to baseline, an 81% decrease was observed for median total testosterone (to 3.4 nmol/L (0.4–12.2); P < 0.0001) and free testosterone (to 0.06 nmol/L (0.01–0.18); P < 0.0001). Median total estradiol decreased by 71% (to 17.6 pmol/L (4.7–35.6); P < 0.0001). Increased serum calcium (P < 0.0001) and phosphate (P = 0.0016) was observed, paralleled by decreased PTH (P = 0.0156) and 1,25-dihydroxyvitamin D3 (P = 0.0134). The stable calcium isotope ratio (δ44/42Ca) decreased (P = 0.0458), indicating net calcium loss from bone. Bone-specific alkaline phosphatase and osteocalcin decreased (P < 0.0001 and P = 0.0056, respectively), periostin tended to decrease (P = 0.0500), whereas sclerostin increased (P < 0.0001), indicating suppressed bone formation. Serum bone resorption markers (TRAP, CTX) were unaltered. Conclusions In adult men, calcium release from the skeleton occurs early following sex steroid deprivation, reflecting early bone resorption. The increase of sclerostin and reduction of bone formation markers, without changes in resorption markers, suggests a dominant negative effect on bone formation in the acute phase.
Use of ERCP in the United States over the past decade
Samuel, Ronald , Umar, Shifa , Abougergi, Marwan S., Lukens, Frank , Carr‐Locke, David L. , Lukens, Frank J., Raimondo, Massimo , Kröner, Paul T. , Bilal, Mohammad

Mayo Clinic

Endoscopy International Open | May 25, 2020 | Volume: 08 | Issue: 06 | Pages: E761-E769

10.1055/a-1134-4873 | PMID 32490161 Get It

Abstract Background and study aims With newer imaging modalities, indications for use of endoscopic retrograde cholangiopancreatography (ERCP) have changed in the last decade. Despite advances in ERCP, paucity in recent literature regarding utilization and outcomes of ERCP exists. Thus, the aim of this study was to assess the inpatient use of ERCP, outcomes, and most common indications. Patients and methods Retrospective-cohort study using the Nationwide Inpatient Sample 2007–2016. All patients with ICD9–10CM procedural codes for ERCP were included. The primary outcome was the use of ERCP. Secondary outcomes included determining procedural specifics (stenting, sphincterotomy and dilation), complications (post-ERCP pancreatitis [PEP], bile duct perforation), hospital length of stay, total hospital costs and charges. Multivariate regression analysis was used to adjust for confounders. Results A total of 1,606,850 patients underwent inpatient ERCP. The mean age was 59 years (60 % female). The total number of ERCPs increased over the last decade. Patients undergoing ERCP in 2016 had greater odds of undergoing bile duct stent placement, pancreatic duct (PD) stenting, biliary dilation, pancreatic sphincterotomy, PEP and biliary perforation. Inpatient mortality decreased. Hospital charges increased, while length of stay (LOS) decreased. Conclusions The number of ERCPs increased in the past decade. Odds of therapeutic interventions and complications increased. The most common principal diagnoses were choledocholithiasis and gallstone-related AP. Hence, physicians must be aware to promptly diagnose and treat complications. These findings may reflect the increased case complexity and fact that ERCP continues to evolve into an increasingly interventional tool, contrasting from its former role as a predominantly diagnostic and gallstone extraction tool.
Tumor-infiltrating lymphocytes and tumor budding refine prognostication in patients with low- and high-risk stage III colon cancers (NCCTG N0147)[Alliance].
Sha, Dan, Lee, Hee Eun , Foster, Nathan R. , Smyrk, Thomas C. , Shi, Qian , Alberts, Steven R. , Sinicrope, Frank A.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 4065-4065

10.1200/jco.2020.38.15_suppl.4065 Get It

4065 Background: Tumor infiltrating lymphocytes (TILs) and tumor budding (linked to epithelial mesenchymal transition) may influence metastatic potential and patient prognosis. We analyzed these features and their relative contribution to survival among low (T1-3 N1) and high (T4 and/or N2) risk groups, defined by the IDEA study, used to inform the duration of adjuvant chemotherapy in stage III colon cancer. Methods: Among 1,532 patients (low risk n=804; high risk n=728) treated in a phase III adjuvant trial of FOLFOX + cetuximab (x 6 months), intraepithelial TIL densities and tumor budding were quantified at microscopy in routine histologic sections. Optimal cutpoints were determined in association with 5-yr disease-free survival (DFS). Relative contribution of variables to DFS was calculated using χ2 from Harrell’s rms R package based on multivariable Cox regression models. Results: In the overall cohort, the tumor budding/TILs combined variable was more robust for predition of DFS than either alone. Budding/TILs was significantly associated with DFS in both low (HRadj, 1.59; 95% CI, 1.02-2.48; p=.0273) and high (HRadj, 2.82; 95% CI, 1.72-4.63; p<.0001) risk patients. We then determined its relative contribution (%) to DFS (Table). Among low risk, budding/TILs ranked second (24.4%) behind KRAS status (45.5%) and ahead of treatment arm (7.2%) and mismatch repair (MMR) status (6.1%). Among high risk, budding/TILs contributed the most to DFS (45.4%) followed by primary tumor sidedness (13.0%), performance status (12.0%), and MMR (10.4%). Conclusions: Tumor budding/TILs provides robust prognostic stratification by risk group to improve anatomic tumor staging. The relative contribution of budding/TILs to DFS was second only to KRAS status in low risk patients, and was the most important predictor of DFS in high risk patients. Evaluation in patients treated with 3 vs 6 mos of adjuvant chemotherapy is warranted. [Table: see text]
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy.
Leibovich, Bradley C. , Miest, Tanner, Gonzalgo, Mark L. , Boorjian, Stephen A. , Tollefson, Matthew K. , Karnes, R. Jeffrey , Frank, Igor, Kroeninger, Tessa, Reckner, Monica, Díaz, Rosa María, Kaesshaefer, Stephen, Whitelaw, Ena C., Brunton, Bethany, Newsom, Alysha N., Peng, Kah Whye, Bexon, Alice, Young, Paul R, Lyon, Timothy D. , Naik, Shruthi , Packiriswamy, Nandakumar

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: TPS3172-TPS3172

10.1200/jco.2020.38.15_suppl.tps3172 Get It

TPS3172 Background: Bladder cancer is a leading cause of cancer death in the United States. Over 90% of bladder cancer cases are urothelial carcinomas (UC) that may present as a non-muscle-invasive (NMIBC) or muscle-invasive disease (MIBC). Standard of care for NMIBC includes transurethral resection of bladder tumor (TURBT), intravesical chemotherapy and immunotherapy with Bacillus Calmette-Guerin (BCG). Patients (pts) with high-grade BCG-refractory NMIBC or MIBC undergo RC, which involves complete bladder removal and pelvic lymphadenectomy. RC severely impacts quality of life with significant morbidity. Oncolytic viruses are showing promise in UC, and MV-NIS has proven efficacy in other tumor types. MV-NIS is an investigational oncolytic measles virus with an excellent safety profile, irrespective of route of administration (n > 100). MV-NIS-related adverse events are limited to infusion reactions and transient CBC changes, and little local toxicity is anticipated with intravesical therapy. Clinical efficacy of this oncolytic may be related to absence of measles immunity. Based on this, the clinical strategy for MV-NIS is focused on targeting immune-privileged sites via intra-tumoral or intravesical routes, alone or in combination with checkpoint inhibitors. We hypothesize that intravesical therapy with oncolytic MV-NIS can improve clinical outcomes for (a) BCG refractory NMIBC pts to avoid or delay the need for RC; and (b) MIBC pts undergoing RC. Methods: This study is enrolling pts undergoing RC who are ineligible to receive neoadjuvant chemotherapy. The trial has 2 stages to (a) determine the safety and tolerability of intravesical MV-NIS, and (b) assess preliminary efficacy. Part (a) includes 4-24 pts in a timing cohort with doses administered at increasing durations (1-4 weeks) prior to RC to establish safety of a single MV-NIS dose. Part (b) includes an expansion cohort (n = 12) to evaluate the safety and efficacy of 2 intravesical doses of MV-NIS at 2-week intervals prior to RC. Safety is assessed using NCI-CTCAE V5 and Clavien-Dindo grading of operative complications. The efficacy endpoint is pathologic stage at time of RC (pT0 rate), which can be compared to pre-study TURBT stage. Additional exploratory studies include PK and PD analyses in urine, blood and tumor. Enrollment is ongoing at 2 Mayo Clinic sites (Rochester, MN and Jacksonville, FL) and the study has now progressed from the timing cohort into the expansion cohort. Clinical trial information: NCT03171493 .
Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma.
Adjei, Alex A. , Powell, Steven , Pandya, Naimish, Kaesshaefer, Stephen, Reckner, Monica, Brown, Cheryl, Díaz, Rosa María, Russell, Luke, Peng, Kah Whye, Wiegert, Erol , Seebach, Frank, Lowy, Israel , Bexon, Alice, Lutzky, Jose , He, Aiwu Ruth , Patel, Manish R. , O'Day, Steven J , Gullo, Giuseppe

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: TPS3161-TPS3161

10.1200/jco.2020.38.15_suppl.tps3161 Get It

TPS3161 Background: VV1 is an oncolytic vesicular stomatitis virus engineered to express human IFNβ to enhance cellular anti-tumor immune responses and tumor selectivity, and the human sodium iodide symporter (NIS) for virus tracking by SPECT imaging. Cancer cells are often hyporesponsive to IFNβ, enabling the efficient spread of VV1 and resulting in increased oncolysis. Differently from other oncolytic viruses, VV1 is suitable for both intra-tumoral (IT) and/or intra-venous (IV) administration. Despite considerable anti-tumor activity with checkpoint inhibitors (CPI) among some malignancies, long term survival and overall cures remain elusive. Prior Ph 1 studies have shown significant anti-tumor activity among several malignancies when VV1 was administered either as monotherapy or in combination with a CPI, despite progression on prior CPI monotherapy. Furthermore, pre- and post-treatment biopsy evaluations after VV1 treatment have demonstrated T cell infiltration and inflammation in both IT injected and non-injected lesions. Among IV treated patients (pts), IFNβ was detectable in the serum correlating with viral replication, making it an effective biomarker. C is a high-affinity potent human IgG4 anti-PD-1 monoclonal antibody. Though approved for use in cutaneous squamous cell carcinoma, C has shown anti-tumor activity, similar to other CPI, in several other indications. Therefore, VV1 and C could be an attractive combination for the immunotherapy for several solid tumors. This study represents the first clinical evaluation of VV1 in combination with C in pts with advanced solid tumors. Methods: The Ph 2 Simon 2 stage five-arm study of IV administration VV1 in combination with IV C will enroll pts with advanced NSCLC, HCC, melanoma & endometrial cancer. Enrolled pts with NSCLC & melanoma will be recent CPI-progressors, whereas enrolled HCC & endometrial cancer will be CPI-naïve. The study’s objectives include assessment of preliminary anti-tumor activity, safety, & immuno-regulatory activity of the combination. Pts will receive IV VV1 once on D1 and IV C once every 3 weeks until confirmed disease progression or intolerable toxicity. Pts enrolled in one melanoma cohort will also receive IT VV1 administered to palpable lesions. Response will be assessed every 9 weeks per RECIST v1.1. The null hypothesis of each cohort’s ORR will be tested versus a one-sided alternative yielding a Type I error rate of 5% and power of 80%. Cohorts will be expanded based on signal of activity. Clinical trial information: NCT .
The six different injection techniques for the temple relevant for soft tissue filler augmentation procedures – Clinical anatomy and danger zones
Cotofana, Sebastian , Gaete, Andres, Hernandez, Claudia A, Bay, Shino, Pavicic, Tatjana , Coimbra, Daniel Dal’Asta , Suwanchinda, Atchima , Swift, Arthur, Nikolis, Andreas , Frank, Konstantin , Suwanchinda, Atchima , Nikolis, Andreas , Frank, Konstantin , Cotofana, Sebastian , Casabona, Gabriela , Green, Jeremy B.

Mayo Clinic

Journal of Cosmetic Dermatology | May 17, 2020 | Volume: 19 | Issue: 7 | Pages: 1570-1579

10.1111/jocd.13491 | PMID 32418303 Get It

AbstractObjectiveThe most promising facial region for inducing pan‐facial effects is the temporal region. The temple displays signs of facial aging itself which include temporal volume loss and increased visibility of the temporal crest, the temporal vasculature, the lateral orbital rim, and the upper zygomatic arch. The objective of this article is to provide a detailed review of temple anatomy pertaining to routinely performed temporal injection techniques, their expected esthetic outcomes as well as the intendant advantages, disadvantages, and procedure pearls.Materials and MethodsThis narrative review is based on the clinical experience of the authors treating the temporal region for esthetic purposes. The postulated outcome of each technique was observed during the routine clinical practice of the authors.ResultsThe temporal region is based on a bony platform consisting of the parietal, frontal, sphenoid, and temporal bones. The overlying soft tissues are arranged in layers which contain the temporal neurovascular structures. The temporal soft tissues consist of 10 parallel layers which vary in their thickness depending on age‐related influences. Six different techniques will be addressed, which include subdermal and interfascial techniques for volumizing, low and high supraperiosteal techniques for volumizing, and supraauricular and temporal lifting techniques.ConclusionThis narrative provides a detailed anatomic overview of the temporal region and describes each commonly performed injection technique with respect to anatomy, esthetic outcome, as well as potential pearls and pitfalls. It is hoped that the description contained herein may guide esthetic practitioners toward safer and more natural outcomes when treating the face.
The Venoarterial Extracorporeal Membrane Oxygenation Weaning Checklist
Mihalj, Maks , Rehfeldt, Kent H., Carrel, Thierry , Stueber, Frank, Luedi, Markus M.

Mayo Clinic

A&A Practice | April 23, 2020 | Volume: 14 | Issue: 6 | Pages: e01199

10.1213/xaa.0000000000001199 | PMID 32392020 Get It

Venoarterial extracorporeal membrane oxygenation (vaECMO) is a well-established treatment option for severe cardiogenic shock of various etiologies. Although trials have explored weaning strategies, a brief and conclusive overview is lacking. We present the different aspects of weaning and provide an evidence- and experienced-based guide for clinicians managing patients under vaECMO in the preweaning, weaning, and postweaning phases.
Strategies to Prevent or Remediate Cancer and Treatment-Related Aging
Agurs‐Collins, Tanya , Ahles, Tim A. , Campisi, Judith , Dale, William , Demark‐Wahnefried, Wendy , Dietrich, Jörg , Fuldner, Rebecca, Gallicchio, Lisa , Green, Paige , Hurria, Arti , Janelsins, Michelle C. , Jhappan, Chamelli, Kirkland, James L. , Kohanski, Ronald A. , Longo, Valter D. , Meydani, Simin Nikbin, Mohile, Supriya G. , Niedernhofer, Laura J. , Nelson, Christian J. , Perna, Frank M. , Schadler, Keri , Schrack, Jennifer A. , Deursen, Jan van, Ness, Kirsten K. , van Deursen, Jan, Niedernhofer, Laura J , Demark-Wahnefried, Wendy , Nelson, Christian J , Ness, Kirsten K , Guida, Jennifer , Schadler, Keri , Scott, Jessica M. , Tracy, Russell P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 22, 2020 | Volume: 113 | Issue: 2 | Pages: 112-122

10.1093/jnci/djaa060 | PMID 32348501 Get It

Abstract Up to 85% of adult cancer survivors and 99% of adult survivors of childhood cancer live with an accumulation of chronic conditions, frailty, and/or cognitive impairments resulting from cancer and its treatment. Thus, survivors often show an accelerated development of multiple geriatric syndromes and need therapeutic interventions. To advance progress in this area, the National Cancer Institute convened the second of 2 think tanks under the auspices of the Cancer and Accelerated Aging: Advancing Research for Healthy Survivors initiative. Experts assembled to share evidence of promising strategies to prevent, slow, or reverse the aging consequences of cancer and its treatment. The meeting identified research and resource needs, including geroscience-guided clinical trials; comprehensive assessments of functional, cognitive, and psychosocial vulnerabilities to assess and predict age-related outcomes; preclinical and clinical research to determine the optimal dosing for behavioral (eg, diet, exercise) and pharmacologic (eg, senolytic) therapies; health-care delivery research to evaluate the efficacy of integrated cancer care delivery models; optimization of intervention implementation, delivery, and uptake; and patient and provider education on cancer and treatment-related late and long-term adverse effects. Addressing these needs will expand knowledge of aging-related consequences of cancer and cancer treatment and inform strategies to promote healthy aging of cancer survivors.